186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice

Abstract A 186 Re-labeled monoclonal antibody (MAb), NR-LU-10, was used for the radioimmunotherapy of a subcutaneous human small cell lung carcinoma xenograft, SHT-1, in nude mice. Biodistribution with specific and irrelevant labeled MAb demonstrated peak tumor uptake of 8% and 3% of the injected dose/g at 2 days, respectively. Dosimetry analysis predicted tumor:whole-body radiation-absorbed dose ratios of 2.43:1 for NR-LU-10 and 0.62:1 for irrelevant MAb. Single-dose toxicity screening estimated a 50% lethal dose within 30 days of 600 µCi (880 cGy of whole-body radiation). As anticipated, a multiple-dose regimen of 490 µCi in four doses over 10 days (720 cGy of whole-body radiation, eight of eight surviving >30 days) was less toxic than a single bolus dose of 430 µCi (644 cGy of whole-body radiation), six of eight surviving >30 days). A multidose radioimmunotherapy regimen was initiated in nude mice bearing 66-mm 3 tumors (total dose, 500 to 600 µCi). Complete remissions (>140 days) were achieved in three of 16 mice, and the remainder showed a mean tumor growth delay of 53 days. Matched doses with irrelevant MAb produced one remission, one treatment-related death, and a mean growth delay of only 20 days in six of eight mice. Thus, in this nonoptimal radioimmunotherapy model, significant antitumor responses were observed using a mildly toxic multiple dosing regimen.